Physician profile
Robert C Kwun
NPI 1457338162
$334,398.56
in general payments reported to CMS, 2019-2025
22 companies · $16K in 2025
The $16K reported for 2025 was more than what 93% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123K · 2020: $39K · 2021: $19K · 2022: $22K · 2023: $86K · 2024: $29K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Consulting Fee: $17K · Travel and Lodging: $16K · Food and Beverage: $4,742 · Honoraria: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,715.36 |
| Consulting Fee | $17,446.00 |
| Travel and Lodging | $15,735.50 |
| Food and Beverage | $4,742.41 |
| Honoraria | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $167,421.48 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $102,042.63 | 2019-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $36,865.98 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $11,234.22 | 2022-2024 | Eylea Hd, Eylea |
| Allergan, INC. | $7,966.26 | 2019-2021 | |
| Alimera Sciences, INC. | $2,675.05 | 2021-2023 | Iluvien, Yutiq |
| US Retina LLC | $2,184.58 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $934.41 | 2023-2025 | Syfovre |
| Becton, Dickinson and Company | $900.00 | 2022 | |
| Abbvie INC. | $727.96 | 2022-2024 | |
| Eyepoint US, INC. | $593.65 | 2021-2024 | |
| Astellas Pharma US INC | $248.41 | 2023-2025 | Izervay |
| Astellas Pharma Global Development | $159.77 | 2025 | Izervay |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Biogen, INC. | $88.23 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $79.23 | 2021-2024 | Vabysmo |
| Amgen INC. | $74.04 | 2025 | Lumakras |
| Glaukos Corporation | $52.66 | 2023 | Iaccess Precision Blade, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kwun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.